Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles
Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isoty...
Saved in:
Published in | Thrombosis research Vol. 136; no. 1; pp. 161 - 163 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Ltd
01.07.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0049-3848 1879-2472 1879-2472 |
DOI | 10.1016/j.thromres.2015.04.031 |
Cover
Abstract | Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.
To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).
Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.
Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.
•aβ2GP1 is a lab criterion in antiphospholipid syndrome•aβ2GP1 comprises antibodies directed to different domains of the molecule•Higher values of IgG aβ2GP1-Dm4/5 in patients with sole positivity for IgG aβ2GP1•No association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events |
---|---|
AbstractList | Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.
To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).
Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.
Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.
•aβ2GP1 is a lab criterion in antiphospholipid syndrome•aβ2GP1 comprises antibodies directed to different domains of the molecule•Higher values of IgG aβ2GP1-Dm4/5 in patients with sole positivity for IgG aβ2GP1•No association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.BACKGROUNDDetermination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories.To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1.OBJECTIVESTo measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1.In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).PATIENTS/METHODSIn this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10).Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.RESULTSGeometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism.Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events.CONCLUSIONMean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events. Abstract Background Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. Objectives To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. Patients/Methods. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC +, IgG aCL +, IgG aβ2GP1 +, n = 32), double (LAC-, IgG aCL +, IgG aβ2GP1 +, n = 23) or single positive (LA-, IgG aCL-, IgG aβ2GP1 +, n = 10). Results Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795 ± 783, 321 ± 181, 29 ± 8 and 5.0 ± 1.0, respectively (ANOVA p < 0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16 ± 0.13, 0.16 ± 0.15 and 0.26 ± 0.15, 0.13 ± 0,11, respectively (ANOVA p < 0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p = 0.04) and double (p = 0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Conclusion Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events. Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti β2-Glycoprotein 1 (aβ2GP1) antibodies] allow physicians to allocate patients into classification (risk) categories. To measure antibodies of IgG isotype directed towards Domain 4/5 (Dm4/5) of β2GP1. In this cross-sectional study we measured IgG aβ2GP1-Dm4/5 in a group of individuals positive for IgG aβ2GP1 and classified as triple (LAC+, IgG aCL+, IgG aβ2GP1+, n=32), double (LAC-, IgG aCL+, IgG aβ2GP1+, n=23) or single positive (LA-, IgG aCL-, IgG aβ2GP1+, n=10). Geometric mean and standard deviation of IgG aβ2GP1 values expressed as Chemiluminescent Units (CU) in triple, double, single positive groups and in 40 healthy individuals were 1795±783, 321±181, 29±8 and 5.0±1.0, respectively (ANOVA p<0.0001). Geometric mean and standard deviation of IgG aβ2GP1-Dm4/5 expressed as Optical Density (OD) in triple, double and single positive groups and in 40 healthy individuals were 0.16±0.13, 0.16±0.15 and 0.26±0.15, 0.13±0,11, respectively (ANOVA p<0.002). Individuals in the single positive group, expressed significantly higher values with respect to triple (p=0.04) and double (p=0.03) positive groups. Approximate OD cut-off value (99° percentile) calculated in 40 normal control subjects is 0.404. Positivity to IgG aβ2GP1-Dm4/5 according to this cutoff was found in only 5 individuals, 3 in triple positive and 2 in single positive groups and was not associated with thromboembolism. Mean level of IgG aβ2GP1-Dm4/5 is higher in single positive group. There is no association between positivity to IgG aβ2GP1-Dm4/5 and thromboembolic events. |
Author | Bison, E. Banzato, A. Zoppellaro, G. Pengo, V. Padayattil Jose, S. Denas, G. Ruffatti, A. Hoxha, A. Tonello, M. Bracco, A. |
Author_xml | – sequence: 1 givenname: V. surname: Pengo fullname: Pengo, V. email: vittorio.pengo@unipd.it organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 2 givenname: A. surname: Ruffatti fullname: Ruffatti, A. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 3 givenname: M. surname: Tonello fullname: Tonello, M. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 4 givenname: A. surname: Hoxha fullname: Hoxha, A. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 5 givenname: E. surname: Bison fullname: Bison, E. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 6 givenname: G. surname: Denas fullname: Denas, G. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 7 givenname: S. surname: Padayattil Jose fullname: Padayattil Jose, S. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 8 givenname: G. surname: Zoppellaro fullname: Zoppellaro, G. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 9 givenname: A. surname: Bracco fullname: Bracco, A. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy – sequence: 10 givenname: A. surname: Banzato fullname: Banzato, A. organization: Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25959581$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUsFqGzEQFSWlcdL-QtDRPqwzWmm9KyilIUndgqGBtmehlWaJ3N2VK8kB_1Y_pN8UuY4vOTRlECON3nsj9OaMnIx-REIuGMwZsMXlep7ugx8CxnkJrJqDmANnr8iENbUsSlGXJ2QCIGTBG9GckrMY1wCsZrJ6Q07LSuZo2IRsr8bkWm8dRpo8vfGDdiMVlxWd3gw5zajv6J_fZbHsd8Zvgk-Y7xmd5tryjs1oPlnXdRhwTFRnsc29j3n1buMsneq71exvOffY0czvXI_xLXnd6T7iu6d8Tn58uv1-_blYfV1-ub5aFUYseCqYEFp2tQZpcnRowKJprDSGi6bt2rpsS64l6IbnTdvyiuvW1rWF1lZCLvg5mR50c-NfW4xJDS4a7Hs9ot9GxRaN5CChKjP04gm6bQe0ahPcoMNOHb8qA94fACb4GAN2yrikk_NjCtr1ioHaO6PW6uiM2jujQKjsTKYvntGPHV4kfjwQMX_Ug8OgonE4GrQuoEnKeveyxIdnEqZ3ozO6_4k7jGu_DWO2QTEVSwXq235u9mPDKoASOPxb4H9e8AgFx9bn |
CitedBy_id | crossref_primary_10_1111_aji_13258 crossref_primary_10_1016_j_ejim_2020_07_020 crossref_primary_10_1016_j_thromres_2019_11_029 crossref_primary_10_1024_0301_1526_a000723 crossref_primary_10_1016_j_reumae_2018_11_012 crossref_primary_10_1177_0961203317692432 crossref_primary_10_1007_s11926_018_0772_y crossref_primary_10_1186_s12948_016_0043_2 crossref_primary_10_1055_s_0042_1749590 crossref_primary_10_1016_j_autrev_2017_09_003 crossref_primary_10_1186_s12916_017_0807_7 crossref_primary_10_1177_0961203316641772 crossref_primary_10_1038_srep23839 crossref_primary_10_1111_jth_13976 crossref_primary_10_1586_1744666X_2015_1080121 crossref_primary_10_1016_j_autrev_2018_08_003 crossref_primary_10_1016_j_autrev_2018_06_011 crossref_primary_10_1016_S1773_035X_20_30096_4 crossref_primary_10_1111_jth_14682 crossref_primary_10_1586_17474086_2016_1140034 crossref_primary_10_1093_rheumatology_kead675 crossref_primary_10_1186_s13075_016_1018_x crossref_primary_10_1016_j_ejim_2022_10_010 crossref_primary_10_1093_rheumatology_kead632 crossref_primary_10_1111_aji_12792 crossref_primary_10_1016_j_jaut_2018_02_002 crossref_primary_10_1016_j_autrev_2016_07_028 crossref_primary_10_1016_j_cca_2018_06_037 crossref_primary_10_1177_09612033231211820 crossref_primary_10_1111_jth_14896 crossref_primary_10_1111_ijlh_12507 crossref_primary_10_1016_j_reuma_2018_11_003 crossref_primary_10_1016_j_autrev_2018_03_018 crossref_primary_10_1016_j_ejim_2023_01_012 crossref_primary_10_1016_j_thromres_2018_07_011 |
Cites_doi | 10.1055/s-0037-1614453 10.1111/j.1365-2796.2011.02362.x 10.1111/jth.12537 10.1182/blood-2004-09-3387 10.1182/blood-2013-11-537704 10.1136/ard.2010.137281 10.1111/jth.12264 10.1182/blood-2002-02-0441 10.1016/j.jaut.2006.09.007 10.1111/j.1538-7836.2009.03674.x 10.1111/j.1538-7836.2009.03555.x 10.1111/j.1538-7836.2009.03588.x 10.1111/j.1538-7836.2006.01753.x 10.1093/intimm/dxf043 10.1177/0961203310395055 10.1055/s-0037-1613055 10.1016/j.thromres.2011.04.021 10.1111/jth.12865 |
ContentType | Journal Article |
Copyright | 2015 Elsevier Ltd Elsevier Ltd Copyright © 2015 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2015 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2015 Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.thromres.2015.04.031 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-2472 |
EndPage | 163 |
ExternalDocumentID | 25959581 10_1016_j_thromres_2015_04_031 S0049384815002030 1_s2_0_S0049384815002030 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZGI ~G- 0SF AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 AAYXX ACLOT CITATION ~HD CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c463t-144a9f7a09c9c9fec0dec8d9cc348bfb72b23a90a83b23bb353abd77d0bd54963 |
IEDL.DBID | .~1 |
ISSN | 0049-3848 1879-2472 |
IngestDate | Sun Sep 28 11:20:14 EDT 2025 Thu Apr 03 07:10:31 EDT 2025 Wed Oct 01 03:08:59 EDT 2025 Thu Apr 24 23:06:41 EDT 2025 Fri Feb 23 02:34:53 EST 2024 Sun Feb 23 10:19:19 EST 2025 Tue Aug 26 16:32:27 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Antibodies Glycoproteins Epitopes Thrombosis Antiphospholipid syndrome |
Language | English |
License | Copyright © 2015 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c463t-144a9f7a09c9c9fec0dec8d9cc348bfb72b23a90a83b23bb353abd77d0bd54963 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 25959581 |
PQID | 1689309052 |
PQPubID | 23479 |
PageCount | 3 |
ParticipantIDs | proquest_miscellaneous_1689309052 pubmed_primary_25959581 crossref_citationtrail_10_1016_j_thromres_2015_04_031 crossref_primary_10_1016_j_thromres_2015_04_031 elsevier_sciencedirect_doi_10_1016_j_thromres_2015_04_031 elsevier_clinicalkeyesjournals_1_s2_0_S0049384815002030 elsevier_clinicalkey_doi_10_1016_j_thromres_2015_04_031 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-07-01 |
PublicationDateYYYYMMDD | 2015-07-01 |
PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Thrombosis research |
PublicationTitleAlternate | Thromb Res |
PublicationYear | 2015 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Galli, Luciani, Bertolini, Barbui (bb0015) 2003; 101 Tripodi, de Groot, Pengo (bb0025) 2011; 270 Pengo, Ruffatti, Tonello, Cuffaro, Banzato, Bison (bb0060) Feb 2 2015 Ambrozic, Avicin, Ichikawa, Kveder, Matsuura, Hojnik (bb0085) 2002; 14 Arvieux, Renaudineau, Mane, Perraut, Krilis, Youinou (bb0080) 2002; 87 Pengo, Biasiolo, Rampazzo, Brocco (bb0020) 1999; 81 Andreoli, Nalli, Motta, Norman, Shums, Encabo (bb0070) 2011; 70 Banzato, Pozzi, Frasson, De Filippis, Ruffatti, Bison (bb0055) 2011; 128 de Laat, Derksen, Urbanus, de Groot (bb0030) 2005; 105 Pengo, Tripodi, Reber, Rand, Ortel, Galli (bb0050) 2009; 7 Iverson, von Muhlen, Staub, Lassen, Binder, Norman (bb0075) 2006; 27 Pengo, Ruffatti, Legnani, Gresele, Barcellona, Erba (bb0010) 2010; 8 Pierangeli, de Groot, Dlott, Favaloro, Harris, Lakos (bb0040) 2011; 20 de Laat, Pengo, Pabinger, Musial, Voskuyl, Bultink (bb0035) 2009; 7 Miyakis, Lockshin, Atsumi, Branch, Brey, Cervera (bb0005) 2006; 4 Pengo, Ruffatti, Del Ross, Tonello, Cuffaro, Hoxha (bb0090) 2013; 11 Devreese, Pierangeli, de Laat, Tripodi, Atsumi, Ortel (bb0045) May 2014; 12 Agostinis, Durigutto, Sblattero, Borghi, Grossi, Guida (bb0065) 2014; 123 Pengo (10.1016/j.thromres.2015.04.031_bb0020) 1999; 81 de Laat (10.1016/j.thromres.2015.04.031_bb0030) 2005; 105 Andreoli (10.1016/j.thromres.2015.04.031_bb0070) 2011; 70 Arvieux (10.1016/j.thromres.2015.04.031_bb0080) 2002; 87 Pengo (10.1016/j.thromres.2015.04.031_bb0010) 2010; 8 Pengo (10.1016/j.thromres.2015.04.031_bb0050) 2009; 7 Miyakis (10.1016/j.thromres.2015.04.031_bb0005) 2006; 4 Devreese (10.1016/j.thromres.2015.04.031_bb0045) 2014; 12 Agostinis (10.1016/j.thromres.2015.04.031_bb0065) 2014; 123 Pengo (10.1016/j.thromres.2015.04.031_bb0060) 2015 Pengo (10.1016/j.thromres.2015.04.031_bb0090) 2013; 11 Galli (10.1016/j.thromres.2015.04.031_bb0015) 2003; 101 Banzato (10.1016/j.thromres.2015.04.031_bb0055) 2011; 128 de Laat (10.1016/j.thromres.2015.04.031_bb0035) 2009; 7 Iverson (10.1016/j.thromres.2015.04.031_bb0075) 2006; 27 Tripodi (10.1016/j.thromres.2015.04.031_bb0025) 2011; 270 Pierangeli (10.1016/j.thromres.2015.04.031_bb0040) 2011; 20 Ambrozic (10.1016/j.thromres.2015.04.031_bb0085) 2002; 14 |
References_xml | – volume: 87 start-page: 599 year: 2002 end-page: 605 ident: bb0080 article-title: Distinguishing features of anti-beta2glycoprotein Iantibodies between patients with leprosy and the antiphospholipid syndrome publication-title: Thromb Haemost – volume: 7 start-page: 1767 year: 2009 end-page: 1773 ident: bb0035 article-title: The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study publication-title: J Thromb Haemost – volume: 81 start-page: 256 year: 1999 end-page: 258 ident: bb0020 article-title: dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies publication-title: Thromb Haemost – volume: 20 start-page: 182 year: 2011 end-page: 908 ident: bb0040 article-title: ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010 publication-title: Lupus – volume: 270 start-page: 110 year: 2011 end-page: 122 ident: bb0025 article-title: Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment publication-title: J Intern Med – year: Feb 2 2015 ident: bb0060 article-title: Antibodies to Domain 1 (Dm1) of β2-Glycoprotein 1 (β2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS) publication-title: J Thromb Haemost – volume: 123 start-page: 3478 year: 2014 end-page: 3487 ident: bb0065 article-title: A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome publication-title: Blood – volume: 14 start-page: 823 year: 2002 end-page: 830 ident: bb0085 article-title: Antibeta(2)-glycoprotein I antibodies in children with atopic dermatitis publication-title: Int Immunol – volume: 105 start-page: 1540 year: 2005 end-page: 1545 ident: bb0030 article-title: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis publication-title: Blood – volume: 128 start-page: 583 year: 2011 end-page: 586 ident: bb0055 article-title: Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS) publication-title: Thromb Res – volume: 101 start-page: 1827 year: 2003 end-page: 1832 ident: bb0015 article-title: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature publication-title: Blood – volume: 12 start-page: 792 year: May 2014 end-page: 795 ident: bb0045 article-title: Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH publication-title: J Thromb Haemost – volume: 11 start-page: 1 year: 2013 end-page: 5 ident: bb0090 article-title: Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile publication-title: J Thromb Haemost – volume: 70 start-page: 380 year: 2011 end-page: 383 ident: bb0070 article-title: Anti-β2glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain4/5: might it be the reason for their innocent’ profile? publication-title: Ann Rheum Dis – volume: 8 start-page: 237 year: 2010 end-page: 242 ident: bb0010 article-title: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome publication-title: J Thromb Haemost – volume: 27 start-page: 266 year: 2006 end-page: 271 ident: bb0075 article-title: Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain4 of beta2-GPI publication-title: J Autoimmun – volume: 7 start-page: 1737 year: 2009 end-page: 1740 ident: bb0050 article-title: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis publication-title: J Thromb Haemost – volume: 4 start-page: 295 year: 2006 end-page: 306 ident: bb0005 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J Thromb Haemost – volume: 81 start-page: 256 year: 1999 ident: 10.1016/j.thromres.2015.04.031_bb0020 article-title: dRVVT is more sensitive than KCT or TTI for detecting Lupus Anticoagulant activity of anti-β2-Glycoprotein-I autoantibodies publication-title: Thromb Haemost doi: 10.1055/s-0037-1614453 – volume: 270 start-page: 110 issue: 2 year: 2011 ident: 10.1016/j.thromres.2015.04.031_bb0025 article-title: Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment publication-title: J Intern Med doi: 10.1111/j.1365-2796.2011.02362.x – volume: 12 start-page: 792 issue: 5 year: 2014 ident: 10.1016/j.thromres.2015.04.031_bb0045 article-title: Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH publication-title: J Thromb Haemost doi: 10.1111/jth.12537 – volume: 105 start-page: 1540 year: 2005 ident: 10.1016/j.thromres.2015.04.031_bb0030 article-title: IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis publication-title: Blood doi: 10.1182/blood-2004-09-3387 – volume: 123 start-page: 3478 year: 2014 ident: 10.1016/j.thromres.2015.04.031_bb0065 article-title: A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome publication-title: Blood doi: 10.1182/blood-2013-11-537704 – volume: 70 start-page: 380 year: 2011 ident: 10.1016/j.thromres.2015.04.031_bb0070 article-title: Anti-β2glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain4/5: might it be the reason for their innocent’ profile? publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.137281 – volume: 11 start-page: 1 year: 2013 ident: 10.1016/j.thromres.2015.04.031_bb0090 article-title: Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile publication-title: J Thromb Haemost doi: 10.1111/jth.12264 – volume: 101 start-page: 1827 year: 2003 ident: 10.1016/j.thromres.2015.04.031_bb0015 article-title: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature publication-title: Blood doi: 10.1182/blood-2002-02-0441 – volume: 27 start-page: 266 year: 2006 ident: 10.1016/j.thromres.2015.04.031_bb0075 article-title: Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain4 of beta2-GPI publication-title: J Autoimmun doi: 10.1016/j.jaut.2006.09.007 – volume: 8 start-page: 237 year: 2010 ident: 10.1016/j.thromres.2015.04.031_bb0010 article-title: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03674.x – volume: 7 start-page: 1737 year: 2009 ident: 10.1016/j.thromres.2015.04.031_bb0050 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03555.x – volume: 7 start-page: 1767 year: 2009 ident: 10.1016/j.thromres.2015.04.031_bb0035 article-title: The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2009.03588.x – volume: 4 start-page: 295 year: 2006 ident: 10.1016/j.thromres.2015.04.031_bb0005 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 14 start-page: 823 year: 2002 ident: 10.1016/j.thromres.2015.04.031_bb0085 article-title: Antibeta(2)-glycoprotein I antibodies in children with atopic dermatitis publication-title: Int Immunol doi: 10.1093/intimm/dxf043 – volume: 20 start-page: 182 year: 2011 ident: 10.1016/j.thromres.2015.04.031_bb0040 article-title: ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010 publication-title: Lupus doi: 10.1177/0961203310395055 – volume: 87 start-page: 599 year: 2002 ident: 10.1016/j.thromres.2015.04.031_bb0080 article-title: Distinguishing features of anti-beta2glycoprotein Iantibodies between patients with leprosy and the antiphospholipid syndrome publication-title: Thromb Haemost doi: 10.1055/s-0037-1613055 – volume: 128 start-page: 583 year: 2011 ident: 10.1016/j.thromres.2015.04.031_bb0055 article-title: Antibodies to domain I of β2Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS) publication-title: Thromb Res doi: 10.1016/j.thromres.2011.04.021 – year: 2015 ident: 10.1016/j.thromres.2015.04.031_bb0060 article-title: Antibodies to Domain 1 (Dm1) of β2-Glycoprotein 1 (β2GP1) correctly classify patients at risk in Antiphospholipid Syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/jth.12865 |
SSID | ssj0017195 |
Score | 2.295981 |
Snippet | Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin (aCL) and anti... Abstract Background Determination of the three recommended tests for the diagnosis of antiphospholipid syndrome [Lupus Anticoagulant (LA), anticardiolipin... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 161 |
SubjectTerms | Antibodies Antibodies, Antiphospholipid - blood Antibodies, Antiphospholipid - immunology Antiphospholipid syndrome Antiphospholipid Syndrome - blood Antiphospholipid Syndrome - immunology beta 2-Glycoprotein I - chemistry beta 2-Glycoprotein I - immunology Cross-Sectional Studies Epitopes Epitopes - chemistry Epitopes - immunology Glycoproteins Hematology, Oncology and Palliative Medicine Humans Immunoglobulin G - blood Immunoglobulin G - immunology Protein Structure, Tertiary Thrombosis |
Title | Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0049384815002030 https://www.clinicalkey.es/playcontent/1-s2.0-S0049384815002030 https://dx.doi.org/10.1016/j.thromres.2015.04.031 https://www.ncbi.nlm.nih.gov/pubmed/25959581 https://www.proquest.com/docview/1689309052 |
Volume | 136 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1879-2472 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier E-journals (Freedom Collection) customDbUrl: eissn: 1879-2472 dateEnd: 20160531 omitProxy: true ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1879-2472 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1879-2472 dateEnd: 20160531 omitProxy: true ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-2472 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017195 issn: 0049-3848 databaseCode: AKRWK dateStart: 19720201 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LatwwUIQESi-l6XObJqjQw-7BWcmSbOu4JE22j4QcGshNSLJMHHbtJfYeculH9UP6TRnZ8tJSQkuLMLZkD2NmRtIMmgdC75MszWHXEZFPLxdxTViUMeqi3BrNCbe06KLSzs6T-SX_dCWuttDREAvj3SrD2t-v6d1qHUamgZrTVVn6GF8umc8GL7rjNG-3c556WT_8tnHzoCmVfRUDLiP_9U9RwjeHvhTBEsxa7-IlupSnjD60QT2kgHYb0clT9CRokHjW_-Qu2nLVM_ToLJyRP0frWdWWpvbegbit8XG9BOMf86nA4-Ml3Ca4LvCP73F0urizdZenAd5TPIax0ws6wdAbyqa0GAhfrq7rBq5FuSpzPNYXXybdMOC4w6Hmd_MCXZ58-Ho0j0JxhcjyhLURGFJaFqkm0kIrnCW5s1kurWU8M4VJYxMzLYnOGDwYwwTTJk_TnJgcbMqEvUTbVV251wgXSaJTExeZ5sDf2OhMOEG4yx23GRd0hMRAUWVD5nFfAGOhBhezGzVwQnlOKMIVcGKEphu4VZ97448Q6cAwNUSWwlqoYHv4N0jXhCndKKqaWBH1m9iNkNxA_iK5f4X13SBVCqa1P6vRlavXgC0BRZJIIuIRetWL24YGYLFCy-ib_8C8hx77Xu94_BZtt7drtw_qVWsOuvlzgHZmHz_Pz-8B2kQkeQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LbtQw0KqKBFwQb7a8jMRh95CuHduJc6xa2gV2qx5aqTfLdhyRajdZkeyhl34UH8I3MU6cFQhVIJAVJbEzmmhmbM_I80DofSLTHHYdEfn0chHXhEWSURfl1mhOuKVFF5W2OE1mF_zTpbjcQYdDLIx3qwxrf7-md6t16JkGak7XZeljfHnGfDZ40R2ngd1-h3uJAqHev9n6edCUZn0ZA55F_vOfwoSv9n0tghXYtd7HS3Q5Txm9bYe6TQPtdqLjh-hBUCHxQf-Xj9COqx6ju4twSP4EbQ6qtjS1dw_EbY2P6hVY_5hPBR4freA2wXWBv3-Lo5Plta27RA0wTvEY-k7O6ATD21A3pcVA-XL9pW7gWpbrMsdjfTafdN2A4xqHot_NU3Rx_OH8cBaF6gqR5QlrI7CkdFakmmQWWuEsyZ2VeWYt49IUJo1NzHRGtGTwYAwTTJs8TXNicjAqE_YM7VZ15V4gXCSJTk1cSM2BwbHRUjhBuMsdt5ILOkJioKiyIfW4r4CxVIOP2ZUaOKE8JxThCjgxQtMt3LpPvvFHiHRgmBpCS2ExVLA__Buka8KcbhRVTayI-k3uRijbQv4iun-F9d0gVQrmtT-s0ZWrN4AtAU2SZETEI_S8F7ctDcBkhSbp3n9gfovuzc4XczX_ePr5JbrvR3ov5Fdot_26ca9B12rNm24u_QBVHiYK |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibodies+to+Domain+4%2F5+%28Dm4%2F5%29+of+%CE%B22-Glycoprotein+1+%28%CE%B22GP1%29+in+different+antiphospholipid+%28aPL%29+antibody+profiles&rft.jtitle=Thrombosis+research&rft.au=Pengo%2C+V.&rft.au=Ruffatti%2C+A.&rft.au=Tonello%2C+M.&rft.au=Hoxha%2C+A.&rft.date=2015-07-01&rft.pub=Elsevier+Ltd&rft.issn=0049-3848&rft.eissn=1879-2472&rft.volume=136&rft.issue=1&rft.spage=161&rft.epage=163&rft_id=info:doi/10.1016%2Fj.thromres.2015.04.031&rft.externalDocID=S0049384815002030 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00493848%2FS0049384815X00089%2Fcov150h.gif |